A phase II trial of SENS-401 to prevent cisplatin-induced ototoxicity in a pediatric population

Trial Profile

A phase II trial of SENS-401 to prevent cisplatin-induced ototoxicity in a pediatric population

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs R-azasetron-besylate (Primary)
  • Indications Chemotherapy-induced damage
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2017 New trial record
    • 17 Oct 2017 This trial is expected to begin in the second half of 2018, according to a Sensorion media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top